Cannabis Drug Reduces Drop Seizures in Severe Epilepsy!
A purified formulation of cannabidiol (Epidiolex, GW Pharmaceuticals) is safe and effective as adjunctive treatment for drop seizures in patients with Lennox-Gastaut syndrome (LGS), new research shows. Epidiolex, given at a dose of 10 mg/kg or 20 mg/kg per day, led to a significantly greater reduction in the frequency of drop seizures than did placebo, investigators report.
@dhitishree LGS is a rare, severe form of epilepsy characterized by frequent drop seizures and severe cognitive impairment. Six medications are approved to treat seizures in patients with the syndrome, but disabling seizures occur in most patients despite these treatments. Epidiolex has been studied in several studies of patients with LGS and Dravet syndrome, with promising results. The current study enrolled 225 patients (mean age around 15 years) with LGS across 30 international sites in a randomized, double-blind, placebo-controlled trial to assess the efficacy and safety of two doses of Epidiolex added to conventional antiepileptic medication: 76 received 20 mg/kg/day Epidiolex, 73 received 10 mg/kg/day Epidiolex, and 76 received placebo. All medications were divided into two doses per day for 14 weeks. Seizure frequency was monitored beginning 4 weeks before baseline and then tracked throughout the 14-week study period and for 4 weeks after the study period.